Prime Medicine (PRME) Competitors $1.46 -0.07 (-4.58%) As of 06/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRME vs. SION, CDXC, XNCR, ORIC, GHRS, TSHA, KROS, BCYC, IOVA, and UPBShould you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include Sionna Therapeutics (SION), ChromaDex (CDXC), Xencor (XNCR), ORIC Pharmaceuticals (ORIC), GH Research (GHRS), Taysha Gene Therapies (TSHA), Keros Therapeutics (KROS), Bicycle Therapeutics (BCYC), Iovance Biotherapeutics (IOVA), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry. Prime Medicine vs. Its Competitors Sionna Therapeutics ChromaDex Xencor ORIC Pharmaceuticals GH Research Taysha Gene Therapies Keros Therapeutics Bicycle Therapeutics Iovance Biotherapeutics Upstream Bio Prime Medicine (NYSE:PRME) and Sionna Therapeutics (NASDAQ:SION) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations. Is PRME or SION more profitable? Sionna Therapeutics' return on equity of 0.00% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Prime MedicineN/A -107.87% -74.97% Sionna Therapeutics N/A N/A N/A Do analysts recommend PRME or SION? Prime Medicine presently has a consensus target price of $10.08, indicating a potential upside of 590.64%. Sionna Therapeutics has a consensus target price of $38.50, indicating a potential upside of 126.60%. Given Prime Medicine's higher possible upside, equities research analysts clearly believe Prime Medicine is more favorable than Sionna Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75Sionna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor PRME or SION? In the previous week, Sionna Therapeutics had 4 more articles in the media than Prime Medicine. MarketBeat recorded 7 mentions for Sionna Therapeutics and 3 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 1.76 beat Sionna Therapeutics' score of 0.74 indicating that Prime Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Sionna Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, PRME or SION? Sionna Therapeutics has lower revenue, but higher earnings than Prime Medicine. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrime Medicine$3.85M49.84-$198.13M-$1.61-0.91Sionna TherapeuticsN/AN/AN/AN/AN/A Does the MarketBeat Community favor PRME or SION? Prime Medicine received 27 more outperform votes than Sionna Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Sionna Therapeutics an outperform vote while only 63.83% of users gave Prime Medicine an outperform vote. CompanyUnderperformOutperformPrime MedicineOutperform Votes3063.83% Underperform Votes1736.17% Sionna TherapeuticsOutperform Votes375.00% Underperform Votes125.00% Do insiders and institutionals hold more shares of PRME or SION? 70.4% of Prime Medicine shares are owned by institutional investors. 22.9% of Prime Medicine shares are owned by insiders. Comparatively, 3.9% of Sionna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryPrime Medicine beats Sionna Therapeutics on 8 of the 13 factors compared between the two stocks. Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRME vs. The Competition Export to ExcelMetricPrime MedicineBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$191.69M$3.12B$5.61B$19.87BDividend YieldN/A1.56%5.28%3.83%P/E Ratio-0.7132.9027.1435.60Price / Sales49.84466.20411.8443.81Price / CashN/A168.6838.2517.51Price / Book1.073.427.064.85Net Income-$198.13M-$72.35M$3.23B$1.02B7 Day Performance-13.61%3.01%0.80%0.90%1 Month Performance14.96%20.80%9.71%2.35%1 Year Performance-81.52%-17.10%32.12%10.79% Prime Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRMEPrime Medicine3.954 of 5 stars$1.46-4.6%$10.08+590.6%-81.0%$191.69M$3.85M-0.71234Positive NewsSIONSionna TherapeuticsN/A$13.97+2.0%$38.50+175.6%N/A$616.41MN/A0.0035CDXCChromaDex2.6188 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120XNCRXencor4.1911 of 5 stars$8.58+7.3%$29.50+243.8%-57.2%$610.65M$127.23M-2.68280Positive NewsORICORIC Pharmaceuticals3.9082 of 5 stars$8.47+3.7%$19.17+126.3%+22.4%$602.12MN/A-4.6580Trending NewsAnalyst RevisionHigh Trading VolumeGHRSGH Research1.7731 of 5 stars$11.56-3.9%$30.43+163.2%+4.0%$601.44MN/A-14.6310Analyst RevisionTSHATaysha Gene Therapies3.8531 of 5 stars$2.79+3.0%$7.29+161.1%-32.2%$598.91M$7.22M4.43180Analyst ForecastAnalyst RevisionKROSKeros Therapeutics3.6591 of 5 stars$14.66+3.6%$37.00+152.4%-72.2%$595.42M$214.71M-2.81100Analyst DowngradeBCYCBicycle Therapeutics3.3634 of 5 stars$8.55+4.0%$25.00+192.4%-64.5%$592.12M$25.72M-2.60240Analyst RevisionIOVAIovance Biotherapeutics4.5276 of 5 stars$1.76+0.6%$13.30+655.7%-72.9%$587.72M$212.68M-1.18500Trending NewsUPBUpstream Bio1.943 of 5 stars$10.66+15.5%$56.50+430.0%N/A$573.44M$2.30M0.0038High Trading Volume Related Companies and Tools Related Companies Sionna Therapeutics Alternatives ChromaDex Alternatives Xencor Alternatives ORIC Pharmaceuticals Alternatives GH Research Alternatives Taysha Gene Therapies Alternatives Keros Therapeutics Alternatives Bicycle Therapeutics Alternatives Iovance Biotherapeutics Alternatives Upstream Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PRME) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRME Stock Free PRME Stock Alerts